​

26081-22086

Phase III intergroup study of radiotherapy versus temozolomide versus radiotherapy with concomitant and adjuvant temozolomide for patients with newly diagnosed anaplastic oligodendroglioma or anaplastic mixed glioma with chromosomal co-deletions of 1p and 19q (Co-Del). (M.van den Bent, F. Dhermain/S. Erridge)

​

40084-22084

Adjuvant treatment for resected head of pancreas adenocarcinoma: a phase III RTOG/SWOG/NCIC/EORTC study involving two randomizations (K. Haustermans for ROG)

​

​

22033-26033

Phase III low grade gliomas with stratification for genetic 1p/19q loss.
(B. Baumert, R. Stupp)

22042-26042

Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a phase II trial 
(D. Weber)

 

22043-30041

Phase III pathological stage T3 a-b R 0-1 N0, pT2 R1 N0 Gleason score 5-10 prostatic carcinoma
(M.Bolla,H. Van Poppel)

 

22051-10052

SUPREMO: a phase III (Scottish Trials Office, UK)
(I. Kunkler, G. Van Tienhoven)

 

26053-22054

CATNON: anaplastic glioma without 1p19q loss (EORTC/NCI-C/RTOG/Cancer UK/HUB/NOA intergroup)
(M.Van den Bent, B. Baumert)

 

22061-26062

Randomized phase III newly diagnosed glioblastoma multiforme in elderly patients (A. Brandes, J. Menten)

 

40054-22062
 (PETACC-6)

Phase III in locally advanced rectal cancer
(E. van Cutsem, K. Haustermans)

 

22071-24071

Randomized phase III trial on postoperative chemoradiation in combination with an EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinoma (HNSCC) with high risk of locoregional recurrence.
(W. Budach, H.Langendijk)

 

08072-22074

CONVERT: concurrent once daily versus radiotherapy twice daily in limited disease SCLC a randomized phase III study
(C. Faivre Finn)

 

 

26082-22801

Temsirolimus (CCI-779) with concomitant radiation therapy, followed by temsirolimus maintenance therapy versus radiochemotherapy with concomitant and adjuvant temozolomide in subjects with newly diagnosed GBM without methylation of the MGMT gene promoter – a randomized multicentre open-label phase II study
(W.Wick, G. Pesce)

 

24081-22082

Randomized phase III study of induction chemotherapy followed by radiotherapy plus cetuximab (RTC) versus RTC versus RT plus cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck
(J. Vermorken/L. Licitra, V. Gregoire)

  

22085-10083

Randomized phase III study of radiation doses and fractionation schedules for DCIS of the breast (H. Westenberg)

 

 

 previous page << 2 >> next page